NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Global Oncolytic Virus Therapy Market - 2019-2026

出版商 DataM Intelligence 商品編碼 745298
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
腫瘤溶解性病毒療法的全球市場 Global Oncolytic Virus Therapy Market - 2019-2026
出版日期: 按訂單生產內容資訊: 英文


第1章 調查範圍·手法

第2章 趨勢與發展

  • 主要市場趨勢與發展

第3章 產業分析

  • 促進因素
  • 阻礙因素
  • 波特的五力分析

第4章 臨床試驗分析

第5章 產品平台分析

第6章 各市場區隔分析

  • 各適應症
  • 各藥物分類
  • 各治療類型

第7章 各地區分析

  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 其他

第8章 競爭情形

  • 市場佔有率/排名分析
  • 市場企業的主要策略
  • 產品基準

第9章 企業簡介

  • Amgen
  • Pfizer
  • Oncolytics Biotech
  • Viralytics
  • Transgene
  • AstraZeneca
  • Lee Pharma
  • Roche
  • Merck
  • SillaJen Inc.

第10章 附錄


Global Oncolytic Virus Therapy Market Overview

The global Oncolytic Virus market is expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.

An oncolytic virus is a virus that mainly infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, the virus releases new infectious virus particles or virions to help destroy the remaining tumor. Oncolytic viruses not only to destroy the tumor cells but also to stimulate host anti-tumor immune system responses. An oncolytic virus is a genetically engineered or naturally occurring virus, and oncolytic virus therapy is a new therapeutic approach for treating cancer and shown promising results globally.

Global Oncolytic Virus Therapy Market - Market Dynamics

The global market for the Oncolytic Virus Therapy Market is primarily driven by the rising prevalence of cancer cases and increasing development of cancer-treating therapies. According to the World Health Organization (WHO), 2015, cancer was responsible for 8.8 million deaths in that year. Technological developments such as natural killer cells and use of combination therapies are also driving the market growth. Further ongoing development of virus therapies globally, which are in the pipeline will further enhance the growth of oncolytic virus therapy market in the forecast period. Moreover, research funding by government and private organizations for cancer treatment aid in the growth of the Oncolytic Virus market.

However, the high cost of oncolytic virus therapy and the immune reaction to the virus based therapies by repeated administration of therapeutics for treating cancer may hinder the market progress.

Global Oncolytic Virus Therapy Market - Segment Analysis

By Application, the oncolytic virus therapy market is segmented into melanoma, prostate cancer, breast cancer, ovarian cancer, and others. Melanoma is accounted for the largest share as most of the cancer therapies are developed for Melanoma cancers. Increasing prostate cancer cases also leading to the strong growth rate in prostate cancer therapies in recent years.

By Drug class, the oncolytic virus therapy market is segmented into Onxy-15, Talimogene laherparepvec, Reolysin, RIGVIR, and others. Talimogene laherparepvec is the largest drug class that accounted for major share in the market, and is mainly attributed to its vast penetration in cancer treatment.

By Therapy Type, the oncolytic virus therapy market is segmented into HSV-Based Oncolytic Viruses, Adenoviruses-Based Oncolytic Viruses, Vaccinia Virus-Based Oncolytic Viruses, Vesicular Stomatitis Virus-Based Oncolytic Viruses, Newcastle Disease Virus-Based Oncolytic Viruses.

Global Oncolytic Virus Therapy Market- Geographical Analysis

North America is the dominant share in the global oncolytic virus therapy market, and it is primarily attributed to factors such as the rise in cancer cases along with technological advancement. Moreover, its broad base of the patient population and the established healthcare infrastructure and the rising disposable income and higher investment in R&D activities contribute to the growth of North America's share.

Asia-Pacific region is expected to be the fastest growing market during the forecast period, owing to the region's rapidly improving healthcare infrastructure and the presence of a broad base of the target population. The high economic growth, geographic business expansions of market players, and the increasing government initiatives.

Global Oncolytic Virus Therapy Market- Competitive Analysis

Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with increased focus on R&D are other ways the leading players improve their market presence. Key players are also bolstering their networks of distribution to expand the geographical scope of their products.

February 2019, Mustang Bio and Nationwide Children's Hospital entered into an exclusive worldwide license agreement to develop an oncolytic virus (c134) to treat Glioblastoma Multiforme.

February 2019, Oncolytics Biotech Inc. is currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that the Spanish Agency for Medicine and Health Products had granted final approval for the forthcoming AWARE-1 window of opportunity study in breast cancer. This study, which represents the first application of Oncolytics' master clinical supply agreement with Roche for the combination of pelareorep with a leading immune checkpoint inhibitor atezolizumab (Tecentriq).

February 2019, Cytonus Therapeutics Inc. announced that it had developed Cargocytes a first-of-its-kind, controllable, cell-based platform technology for delivery of biologics. Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies, and oncolytic viruses.

September 2018, Boehringer Ingelheim acquired oncolytic virus startup ViraTherapeutics. The takeover was focused on vesicular stomatitis virus (VSV) candidates Boehringer sees becoming critical components of its efforts to gain ground in the immuno-oncology sector.

Why Purchase the Report?

  • Visualize the composition of the global Oncolytic Virus Therapy Market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.
  • Identify commercial opportunities in global Oncolytic Virus Therapy Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global Oncolytic Virus Therapy Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents


  • 1.1. Research Methodology
  • 1.2. Scope of the market


  • 2.1. Key Trends and Developments


  • 3.1. Drivers
  • 3.2. Restraints
  • 3.3. Supply Chain Analysis
  • 3.4. Epidemiology
  • 3.5. Key Developments


  • 4.1. By Therapy Type
    • 4.1.1. HSV-based Oncolytic Viruses
    • 4.1.2. Adenoviruses-based Oncolytic Viruses
    • 4.1.3. Vaccinia Virus-based Oncolytic Viruses
    • 4.1.4. Vesicular Stomatitis Virus-based Oncolytic Viruses
    • 4.1.5. Newcastle Disease Virus-based Oncolytic Viruses
  • 4.2. By Applications
    • 4.2.1. Melanoma
    • 4.2.2. Prostate Cancer
    • 4.2.3. Breast Cancer
    • 4.2.4. Ovarian Cancer
    • 4.2.5. Others
  • 4.3. By Drug Class
    • 4.3.1. Onxy-15
    • 4.3.2. Talimogene laherparepvec
    • 4.3.3. Reolysin
    • 4.3.4. RIGVIR
    • 4.3.5. Others


  • 5.1. Geographic Overview
  • 5.2. North America
    • 5.2.1. U.S.
    • 5.2.2. Canada
    • 5.2.3. Mexico
  • 5.3. Europe
    • 5.3.1. Germany
    • 5.3.2. U.K.
    • 5.3.3. France
    • 5.3.4. Rest of Europe
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5. Asia Pacific
    • 5.5.1. China
    • 5.5.2. India
    • 5.5.3. Japan
    • 5.5.4. Australia
    • 5.5.5. Rest of Asia Pacific
  • 5.6. Rest of World


  • 6.1. Competitive Scenario
  • 6.2. Key Strategies adopted by Manufacturers
  • 6.3. Product Benchmarking


  • 7.1. Pfizer Inc.
  • 7.2. Merck & Co.
  • 7.3. Oncolytics Biotech
  • 7.4. Viralytics, Transgene SA
  • 7.5. Oncolys BioPharma
  • 7.6. PsiOxus Therapeutics
  • 7.7. SillaJen Biotherapeutics
  • 7.8. Amgen
  • 7.9. F. Hoffmann-La Roche Ltd.
  • 7.10. Novartis International AG
  • 7.11. TILT Biotherapeutics


  • 8.1. Sources
  • 8.2. List of Tables
  • 8.3. Expert Panel Validation
  • 8.4. Disclaimer
  • 8.5. Contact Us